Your browser doesn't support javascript.
loading
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
Desterke, Christophe; Martinaud, Christophe; Ruzehaji, Nadira; Le Bousse-Kerdilès, Marie-Caroline.
Affiliation
  • Desterke C; Inserm UMS33, Paul Brousse Hospital, 14 Avenue Paul-Vaillant Couturier, 94800 Villejuif, France.
  • Martinaud C; Department of Clinical Biology, HIA Percy, 101 Avenue Henri Barbusse, 92140 Clamart, France ; Inserm UMR-S1197, Paul Brousse Hospital, 14 Avenue Paul-Vaillant Couturier, 94800 Villejuif, France.
  • Ruzehaji N; Inserm UMR-S1197, Paul Brousse Hospital, 14 Avenue Paul-Vaillant Couturier, 94800 Villejuif, France.
  • Le Bousse-Kerdilès MC; Inserm UMR-S1197, Paul Brousse Hospital, 14 Avenue Paul-Vaillant Couturier, 94800 Villejuif, France ; French Intergroup on Myeloproliferative Neoplasms (FIM), France ; GDR 2697 Micronit, France.
Mediators Inflamm ; 2015: 415024, 2015.
Article in En | MEDLINE | ID: mdl-26640324
ABSTRACT
Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm where severity as well as treatment complexity is mainly attributed to a long lasting disease and presence of bone marrow stroma alterations as evidenced by myelofibrosis, neoangiogenesis, and osteosclerosis. While recent understanding of mutations role in hematopoietic cells provides an explanation for pathological myeloproliferation, functional involvement of stromal cells in the disease pathogenesis remains poorly understood. The current dogma is that stromal changes are secondary to the cytokine "storm" produced by the hematopoietic clone cells. However, despite therapies targeting the myeloproliferation-sustaining clones, PMF is still regarded as an incurable disease except for patients, who are successful recipients of allogeneic stem cell transplantation. Although the clinical benefits of these inhibitors have been correlated with a marked reduction in serum proinflammatory cytokines produced by the hematopoietic clones, further demonstrating the importance of inflammation in the pathological process, these treatments do not address the role of the altered bone marrow stroma in the pathological process. In this review, we propose hypotheses suggesting that the stroma is inflammatory-imprinted by clonal hematopoietic cells up to a point where it becomes "independent" of hematopoietic cell stimulation, resulting in an inflammatory vicious circle requiring combined stroma targeted therapies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Primary Myelofibrosis / Inflammation Limits: Humans Language: En Journal: Mediators Inflamm Journal subject: BIOQUIMICA / PATOLOGIA Year: 2015 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Marrow / Primary Myelofibrosis / Inflammation Limits: Humans Language: En Journal: Mediators Inflamm Journal subject: BIOQUIMICA / PATOLOGIA Year: 2015 Document type: Article Affiliation country: